The Controlled Substances Act, signed in 1970, establishes psilocybin mushrooms, a psychoactive drug, as a Schedule I substance. This means the federal government believes the substance has high potential for abuse and no accepted medical use for treatment in the United States. Today, however, we are seeing states and cities decriminalize psychedelics like psilocybin, ketamine, ayahuasca, and DMT for medical or personal use and beginning to explore their pharmaceutical properties.
Having blazed a trail in the cannabis space, Manzuri Law attorneys are able to draw on experience from the earliest days of the cannabis industry to address and mitigate crossover issues with psychedelics, from taking advantage of market opportunities associated with government-approved psychedelic drugs to advising investors on local decriminalization efforts. Much like cannabis, the movement to decriminalize and further research psilocybin and other entheogens is moving ahead at a quick pace at both the state and municipal levels.
Our firm provides the following services in this rapidly-expanding area of the law: